Quarterly report · Q3
9987.TEDINET S100STF5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.81T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.76T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥26.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥24.4bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥29.0bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥27.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥37.1bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥27.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥25.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥25.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥18.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.30T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥893.1bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥411.1bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥412.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥178.6bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥310.3 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.63 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥208.46 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 31.5% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥12m |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥39.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.8bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥30.4bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥199.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥22.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥177.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥808m |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.75T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.71T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥39.2bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥22.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.06T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥1.81T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥247.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥26.6bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥27.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥161.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥21.7bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥139.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥854m |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.69T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.65T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥38.8bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥1.96T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥1.76T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥205.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥24.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 354
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | CurrentYTDDuration | 26520000000 | JPY |
| Interest income noi | Prior1YTDDuration | 116000000 | JPY |
| Interest income noi | CurrentYTDDuration | 127000000 | JPY |
| Dividends income noi | Prior1YTDDuration | 1162000000 | JPY |
| Dividends income noi | CurrentYTDDuration | 1218000000 | JPY |
| Equity in earnings of affiliates noi | Prior1YTDDuration | 1006000000 | JPY |
| Equity in earnings of affiliates noi | CurrentYTDDuration | 683000000 | JPY |
| Real estate rent noi | Prior1YTDDuration | 307000000 | JPY |
| Real estate rent noi | CurrentYTDDuration | 224000000 | JPY |
| Other noi | Prior1YTDDuration | 690000000 | JPY |
| Other noi | CurrentYTDDuration | 642000000 | JPY |
| Non operating income | Prior1YTDDuration | 3282000000 | JPY |
| Non operating income | CurrentYTDDuration | 2895000000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 32000000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 33000000 | JPY |
| Rent expenses on real estates noe | Prior1YTDDuration | 226000000 | JPY |
| Rent expenses on real estates noe | CurrentYTDDuration | 185000000 | JPY |
| Other noe | Prior1YTDDuration | 150000000 | JPY |
| Other noe | CurrentYTDDuration | 154000000 | JPY |
| Non operating expenses | Prior1YTDDuration | 409000000 | JPY |
| Non operating expenses | CurrentYTDDuration | 373000000 | JPY |
| Ordinary income | Prior1YTDDuration | 27289000000 | JPY |
| Ordinary income | CurrentYTDDuration | 29042000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration | 9000000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration | 286000000 | JPY |
| Gain on sales of investment securities ei | Prior1YTDDuration | 1000000 | JPY |
| Gain on sales of investment securities ei | CurrentYTDDuration | 6818000000 | JPY |
| Gain on transfer of business ei | Prior1YTDDuration | 19000000 | JPY |
| Gain on transfer of business ei | CurrentYTDDuration | 25000000 | JPY |
| Reversal of reserve for loss on anti monopoly act ei | Prior1YTDDuration | － | JPY |
| Reversal of reserve for loss on anti monopoly act ei | CurrentYTDDuration | 1122000000 | JPY |
| Other ei | Prior1YTDDuration | 1000000 | JPY |
| Other ei | CurrentYTDDuration | 0 | JPY |
| Extraordinary income | Prior1YTDDuration | 32000000 | JPY |
| Extraordinary income | CurrentYTDDuration | 8254000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1YTDDuration | 114000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | CurrentYTDDuration | 223000000 | JPY |
| Loss on valuation of investment securities el | Prior1YTDDuration | 64000000 | JPY |
| Loss on valuation of investment securities el | CurrentYTDDuration | 7000000 | JPY |
| Other el | Prior1YTDDuration | 123000000 | JPY |
| Other el | CurrentYTDDuration | 13000000 | JPY |
| Extraordinary loss | Prior1YTDDuration | 302000000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 244000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 27019000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 37051000000 | JPY |
| Income taxes | Prior1YTDDuration | 8881000000 | JPY |
| Income taxes | CurrentYTDDuration | 11568000000 | JPY |
| Profit loss | Prior1YTDDuration | 18137000000 | JPY |
| Profit loss | CurrentYTDDuration | 25483000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | -23000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |